RESULTS FROM A 52-WEEK RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDYOFA NOVEL, INTRA-ARTICULAR WNT PATHWAY INHIBITOR (SM04690) FOR THE TREATMENT OF KNEE OSTEOARTHRITIS

被引：0

作者：

Yazici, Y. ^{[1
]}

McAlindon, T. ^{[2
]}

Gibofsky, A. ^{[3
,4
]}

Lane, N. ^{[5
]}

Clauw, D. ^{[6
]}

Grifman, M.

Swearingen, C. ^{[1
]}

DiFrancesco, A. ^{[1
]}

Tambiah, J. ^{[1
]}

Hochberg, M. ^{[7
]}

机构：

[1] Samumed LLC, San Diego, CA USA

[2] Tufts Med Ctr, Boston, MA 02111 USA

[3] Weill Cornell Med, New York, NY USA

[4] Hosp Special Surg, 535 E 70th St, New York, NY 10021 USA

[5] Univ Calif Davis, Davis, CA 95616 USA

[6] Univ Michigan, Ann Arbor, MI 48109 USA

[7] Univ Maryland, Sch Med, Baltimore, MD 21201 USA

来源：

JCR-JOURNAL OF CLINICAL RHEUMATOLOGY | 2018年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

432

引用

页码：S137 / S137

页数：1

共 50 条

[31] COMPARISON OF INTRA-ARTICULAR SHAM AND VEHICLE INJECTION FROM A PHASE 2B TRIAL OF SM04690, A SMALL-MOLECULE WNT INHIBITOR, FOR KNEE OSTEOARTHRITIS
Yazici, Y.
Tambiah, J.
Swearingen, C.
Kennedy, S.
Strand, V.
Cole, B.
Hochberg, M.
Bannuru, R.
McAlindon, T.
OSTEOARTHRITIS AND CARTILAGE, 2019, 27 : S241 - S242
[32] INTEGRATED SAFETY SUMMARY OF THE NOVEL, INTRA-ARTICULAR AGENT LORECIVIVINT (SM04690), A CLK/DYRK1A INHIBITOR THAT MODULATES THE WNT PATHWAY, IN SUBJECTS WITH KNEE OSTEOARTHRITIS
Kennedy, Sarah
Simsek, Ismail
Swearingen, Christopher J.
Tambiah, Jeyanesh
Damatarca, Cristina
Yazici, Yusuf
Lane, Nancy E.
Hochberg, Marc C.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2020, 26 : 121 - 121
[33] Intra-articular hyaluronan injections for the treatment of osteoarthritis of the knee: A randomized, double blind, placebo controlled study
Tamir, E
Robinson, D
Koren, R
Agar, G
Halperin, N
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2001, 19 (03) : 265 - 270
[34] Safety Profile to Date of the Novel, Intra-articular Agent Lorecivivint (LOR; SM04690), a CLK/DYRK1A Inhibitor That Modulates the Wnt Pathway, in Subjects with Knee Osteoarthritis
Simsek, Ismail
Swearingen, Chris
Kennedy, Sarah
Tambiah, Jeyanesh
Yazici, Yusuf
Lane, Nancy
Hochberg, Marc C.
ARTHRITIS & RHEUMATOLOGY, 2019, 71
[35] Efficacy and safety of intra-articular injection of tropomyosin receptor kinase A inhibitor in painful knee osteoarthritis: a randomized, double-blind and placebo-controlled study
Krupka, E.
Jiang, G. -L.
Jan, C.
OSTEOARTHRITIS AND CARTILAGE, 2019, 27 (11) : 1599 - 1607
[36] INTEGRATED SAFETY SUMMARY OF THE NOVEL, INTRA-ARTICULAR AGENT LORECIVIVINT (LOR; SM04690), A CLK/DYRK1A INHIBITOR THAT MODULATES THE WNT PATHWAY, IN SUBJECTS WITH KNEE OSTEOARTHRITIS
Simsek, I.
Swearingen, C.
Kennedy, S.
Tambiah, J.
Damatarca, C.
Yazici, Y.
Lane, N.
Hochberg, M.
OSTEOPOROSIS INTERNATIONAL, 2020, 31 (SUPPL 1) : S606 - S607
[37] Safety, tolerability and efficacy of intra-articular Progenza in knee osteoarthritis: a randomized double-blind placebo-controlled single ascending dose study
Kuah, D.
Sivell, S.
Longworth, T.
James, K.
Guermazi, A.
Cicuttini, F.
Wang, Y.
Craig, S.
Comin, G.
Robinson, D.
Wilson, J.
JOURNAL OF TRANSLATIONAL MEDICINE, 2018, 16
[38] Safety, tolerability and efficacy of intra-articular Progenza in knee osteoarthritis: a randomized double-blind placebo-controlled single ascending dose study
D. Kuah
S. Sivell
T. Longworth
K. James
A. Guermazi
F. Cicuttini
Y. Wang
S. Craig
G. Comin
D. Robinson
J. Wilson
Journal of Translational Medicine, 16
[39] Intra-Articular Etanercept Treatment in Inflammatory Arthritis: A Randomized Double-Blind Placebo-Controlled Trial.
Aalbers, Caroline J.
Gerlag, Danielle M.
Vos, Koen
Wolbink, Gertjan
Landewe, R.
Tak, Paul P.
ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S574 - S575
[40] THE NOVEL, INTRA-ARTICULAR CLK/DYRK1A INHIBITOR LORECIVIVINT (SM04690), A WNT PATHWAY MODULATOR, IMPROVED RESPONDER OUTCOMES IN SUBJECTS WITH KNEE OSTEOARTHRITIS: A POST HOC ANALYSIS FROM A PHASE 2B TRIAL
Tambiah, J.
Kennedy, S.
Swearingen, C.
Yazici, Y.
OSTEOPOROSIS INTERNATIONAL, 2020, 31 (SUPPL 1) : S45 - S46

← 1 2 3 4 5 →